Form 4: PharmaCyte Director Reports Stock & Option Activity

PharmaCyte Biotech Director Jonathan L. Schechter reported the acquisition of common stock and stock options, alongside shares withheld for tax purposes, with one transaction noted as a late filing.

Summary

• Jonathan L. Schechter, a Director of PharmaCyte Biotech, Inc. (PMCB), acquired 150,000 shares of common stock on December 12, 2025, at a price of $0, increasing his beneficial ownership to 200,000 shares.
• On the same date, 67,500 shares were disposed of at $1.02 per share, representing shares withheld by the Issuer to satisfy tax liability upon the vesting of restricted stock units, reducing his beneficial ownership to 132,500 shares.
• Mr. Schechter also acquired 63,233 stock options (right to buy) on April 25, 2025, with an exercise price of $1.22 per share.
• These options are set to vest in full on the date of the Issuer's next annual meeting of stockholders, contingent on Mr. Schechter's continued service.
• The expiration date for these stock options is April 24, 2035.
• The filing of the stock option transaction was late due to an inadvertent administrative error, not an error by Mr. Schechter.
• A Power of Attorney was executed on December 12, 2025, appointing several individuals to execute and file Forms 3, 4, and 5 on behalf of Jonathan L. Schechter, ensuring compliance with Section 16 of the Securities Exchange Act of 1934.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. The director received significant equity compensation (stock and options), indicating continued alignment with the company's performance. However, the shares withheld for tax purposes and the noted administrative error for a late filing slightly temper the overall positive sentiment.

Positives

• Director Jonathan L. Schechter received a grant of 150,000 shares of common stock and 63,233 stock options, aligning his interests with shareholders.
• The stock options have a long expiration date (April 24, 2035), providing a long-term incentive for the director.

Negatives

• 67,500 shares were withheld by the Issuer to cover tax liabilities upon the vesting of restricted stock units, which reduces the director's direct shareholdings.
• One transaction (the acquisition of stock options on April 25, 2025) was filed late due to an administrative error.

Future Outlook

The acquired stock options for Jonathan L. Schechter are scheduled to vest in full on the date of the Issuer's next annual meeting of stockholders, provided he continues his service to the company.

Management Comments

• "This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter."

Industry Context

This filing represents a routine insider transaction report, detailing changes in a director's beneficial ownership and equity compensation. Such reports are standard practice for publicly traded companies and provide transparency into executive and director holdings, which can sometimes signal management's confidence in the company's future.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency into director compensation and equity holdings, which can influence perceptions of management alignment and confidence.
• Employees: The vesting conditions for the options (continued service) reinforce the importance of retaining key personnel.

Next Steps

• The acquired stock options will vest in full on the date of the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

PharmaCyte Biotech, PMCB, Jonathan Schechter, Form 4, Insider Transaction, Stock Options, Equity Compensation, Director, Beneficial Ownership, SEC Filing